BK polyomavirus (BKPyV) often reactivates after kidney transplantation, causing BKPyV-associated nephropathy (BKPyVAN) in 1%-10% of cases with a potential detrimental effect on allograft survival. Kidney transplant recipients are regularly screened for BKPyV DNA in plasma. As this strategy may not always reduce the risk of BKPyVAN, other predictive markers are needed. To evaluate the role of pretransplant BKPyV-specific antibody, 210 kidney transplant recipients and 130 donors were screened for BKPyV DNA and BKPyV-specific antibodies. We found that the donor BKPyV immunoglobulin G (IgG) seroprevalence and antibody level were strongly associated with BKPyV-DNAemia and BKPyVAN, although multivariant analysis found the presence of anti-BKPyV-specific antibodies as a predictive factor only for BKPyV-DNAemia. The pretransplant recipient status had no effect on posttransplant BKPyV-DNAemia and BKVAN. BKPyV IgG levels remained stable in BKPyV-negative recipients during 1-year follow-up, while a considerable increase was observed in BKPyV-positive patients. The presence of anti-BKPyV-specific antibodies in kidney allograft donors is a good and reliable predictive marker for posttransplant BKPyV replication with relevance to risk stratification in transplant recipients.

• MeSH
• imunoglobulin G MeSH
• intersticiální nefritida * komplikace   MeSH
• lidé MeSH
• polyomavirové infekce * MeSH
• séroepidemiologické studie MeSH
• transplantace ledvin * škodlivé účinky   MeSH
• virus BK * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Importance: Recurrent respiratory papillomatosis (RRP) is a rare benign chronic disease of the larynx etiologically linked with the infection of low-risk human papillomavirus (HPV). Combination of surgical and immunomodulatory therapy has limited success. Possible use of prophylactic HPV vaccine that includes HPV-6 and HPV-11 antigens has been studied. Objective: To evaluate if the HPV vaccination is associated with a lower number of recurrences requiring surgical intervention in patients with new and recurrent RRP. Design, Setting, and Participants: This was a non-placebo-controlled intervention study. Enrollment data were collected from October 2011 to August 2013. The patients were followed up at 1 month, 12 months, and 5 years after the third dose of the vaccine and clinically monitored until December 31, 2018. Data were analyzed from 2019 to 2021. Altogether, 50 adults with active RRP were enrolled and followed up in referral centers. For the final outcome, follow-up data for 42 patients were available. Eight patients who did not fulfill the protocol were excluded. Interventions: All patients received HPV vaccine as an adjuvant treatment and were clinically followed up. When RRP progression or a significant recurrent lesion was detected, surgical removal via direct laryngoscopy was indicated. No adjuvant therapy with antiviral or biological agents was used. Main Outcomes and Measures: This study compared the prevaccination and postvaccination positivity for HPV-specific antibodies. The main outcome was the difference in the frequency of RRP recurrences in the prevaccination and postvaccination period. Results: A total of 50 patients with RRP were enrolled (median [SD] age, 41.5 [12.3] years [range, 21-73 years]; 39 [78%] men and 11 [22%] women). After HPV vaccination, patients with previously no HPV-specific antibodies showed seroconversion, and all patients developed 100-fold higher levels of HPV vaccine type-specific antibodies compared with the prevaccination period. In patients with recurrent RRP, decreased frequency of recurrences requiring surgical treatment was present after vaccination (from 0.85 to 0.36 recurrences/y). No difference in postvaccination recurrences was found between patients with newly diagnosed and recurrent RRP. Conclusions and Relevance: In this nonrandomized clinical trial, the frequency of RRP recurrences was significantly lower after HPV vaccination, and patients with RRP thus had a reduced burden of disease. Because no difference was detected in the frequency of recurrent postvaccination lesions in patients with new and recurrent disease, it appears that both groups showed equal benefit following HPV vaccination. These findings suggest that the earlier that patients with RRP receive HPV vaccine, the sooner they may show reduced burden of disease. Trial Registration: EudraCT Identifier: 2011-002667-14; ClinicalTrials.gov Identifier: NCT01375868.

• MeSH
• Alphapapillomavirus * MeSH
• dospělí MeSH
• infekce dýchací soustavy * prevence a kontrola   MeSH
• infekce papilomavirem * prevence a kontrola   MeSH
• lidé MeSH
• vakcinace MeSH
• vakcíny proti papilomavirům * MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• práce podpořená grantem MeSH

BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st-2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with "non-reactive" anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.

• Publikační typ
• časopisecké články MeSH

BACKGROUND: The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis. METHODS: This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment. RESULTS: The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients. CONCLUSIONS: The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.

• MeSH
• časové faktory MeSH
• lidé středního věku MeSH
• lidé MeSH
• lidský papilomavirus 16 imunologie   MeSH
• míra přežití MeSH
• nádory orofaryngu krev   mortalita   terapie   MeSH
• následné studie MeSH
• onkogenní proteiny virové imunologie   MeSH
• Papillomavirus E7 - proteiny imunologie   MeSH
• prediktivní hodnota testů MeSH
• prognóza MeSH
• prospektivní studie MeSH
• protilátky virové krev   MeSH
• represorové proteiny imunologie   MeSH
• skvamocelulární nádory krev   mortalita   terapie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

• Publikační typ
• abstrakt z konference MeSH

Currently, three prophylactic HPV vaccines are commercially available to prevent HPV 16/18 infection and associated lesions. The aim of the study was to assess markers of HPV infection in women/girls before vaccination and to ascertain the prevalence and spectrum of post-vaccination HPV types. Three hundred and thirty subjects of which 75 were virgins were enrolled. Before the first dose of the HPV vaccine and 1, 3 and 5 years after the completion of HPV vaccination, the samples for cytology, HPV detection and anti-HPV antibody response were taken. At enrolment, HPV DNA was detected in 38% of sexually active girls/women. At the first, second and third follow-up, HPV DNA was found in 40, 45, and 39% of them. The seroprevalence rates to HPV 6, 11, 16 and 18 in these subjects were 31, 21, 18 and 10%. On the follow-up significantly higher levels of antibodies to HPV 16/18 were found after application of divalent vaccine. Results of the study demonstrate high prevalence of HPV infection in young women. In a substantial number of women, HPV-specific antibodies as well as high-risk HPV types were detected. HPV-specific antibodies were also frequently found in non-sexually active girls. The acquisition of HPV after the onset of sexual life was very fast.

• MeSH
• cervix uteri patologie   virologie   MeSH
• DNA virů analýza   MeSH
• dospělí MeSH
• infekce papilomavirem epidemiologie   prevence a kontrola   MeSH
• kohortové studie MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• Papillomaviridae izolace a purifikace   MeSH
• protilátky virové krev   MeSH
• séroepidemiologické studie MeSH
• vakcíny proti papilomavirům aplikace a dávkování   imunologie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Recently, novel small DNA viruses (Human Polyomavirus HPyV6, HPyV7, HPyV9, Human Bocavirus HBoV1, Anelloviruses TTMV and TTMDV) have been discovered. Although these viruses belong to different family, they are widespread in population and they all presumably cause common lifelong infections. There is an increasing consideration that novel small DNA viruses play the key role as emerging opportunistic pathogens after reactivation in immunocompromised patients. The aim of the project is to gain knowledge of prevalence and biology of the newly discovered DNA viruses in healthy population and in immunocompromised individuals. The proposed study includes detection of viral DNA, determination of viral load, searching the persistence of the viruses and the presence of virus specific antibodies. In immunocompromised patient we will evaluate the possible clinical manifestation of viral infections.

Během posledních let byla objevena řada nových malých DNA virů (lidské polyomaviry HPyV6, HPyV7, HPyV9, lidský bocavirus HBoV1, anelloviry TTMV a TTMDV). Přestože tyto viry nepatří do jedné skupiny, všechny se pravděpodobně vyskytují běžně v lidské populaci, způsobují celoživotní perzistentní infekci organismu. K reaktivaci s možnými patologickými následky pak může docházet především u imunokompromitovaných jedinců. V tomto projektu se zaměříme na detekci a sledování perzistence nově objevených DNA virů u zdravých a imunokompromitovaných jedinců. Cílem studie je zjistit virovou nálož, variabilitu genomů a přítomnost virově specifických protilátek. U imunokompromitivaných jedinců budeme analyzovat klinické projevy, které mohou souviset s virovou infekcí.

• MeSH
• Anelloviridae MeSH
• DNA virů MeSH
• ELISA MeSH
• kvantitativní polymerázová řetězová reakce MeSH
• lidský bocavirus MeSH
• polyomavirové infekce MeSH
• protilátky virové MeSH
• transplantace hematopoetických kmenových buněk MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• hematologie a transfuzní lékařství
• virologie
• biologie
• NLK Publikační typ
• závěrečné zprávy o řešení grantu IGA MZ ČR

Human polyomaviruses HPyV6, HPyV7, TSPyV, HPyV9, MWPyV, and KIPyV have been discovered between 2007 and 2012. TSPyV causes a rare skin disease trichodysplasia spinulosa in immunocompromised patients, the role of remaining polyomaviruses in human pathology is not clear. In this study, we assessed the occurrence of serum antibodies against above polyomaviruses in healthy blood donors. Serum samples were examined by enzyme-linked immunoassay (ELISA), using virus-like particles (VLPs) based on the major VP1 capsid proteins of these viruses. Overall, serum antibodies against HPyV6, HPyV7, TSPyV, HPyV9, MWPyV, and KIPyV were found in 88.2%, 65.7%, 63.2%, 31.6%, 84.4%, and 58%, respectively, of this population. The seroprevalence generally increased with age, the highest rise we observed for HPyV9 and KIPyV specific antibodies. The levels of anti-HPyV antibodies remained stable across the age-groups, except for TSPyV and HPyV9, where we saw change with age. ELISAs based on VLP and GST-VP1 gave comparable seroprevalence for HPyV6 antibodies (88.2% vs.85.3%) but not for HPyV7 antibodies (65.7% vs. 77.2%), suggesting some degree of crossreactivity between HPyV6 and HPyV7 VP1 proteins. In conclusion, these results provide evidence that human polyomaviruses HPyV6, HPyV7, TSPyV, HPyV9, MwPyV, and KIPyV circulate widely in the Czech population and their seroprevalence is comparable to other countries.

• MeSH
• dárci krve * MeSH
• dospělí MeSH
• hostitel s imunodeficiencí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• myši MeSH
• polyomavirové infekce epidemiologie   imunologie   virologie   MeSH
• Polyomavirus klasifikace   genetika   imunologie   MeSH
• protilátky virové krev   MeSH
• senioři MeSH
• séroepidemiologické studie MeSH
• virion imunologie   izolace a purifikace   MeSH
• virové plášťové proteiny genetika   imunologie   MeSH
• zdraví dobrovolníci pro lékařské studie MeSH
• zkřížené reakce MeSH
• zvířata MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• myši MeSH
• senioři MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Československo epidemiologie   MeSH

Monitoring of prevalence of HPV types in vaccinal population of Czech women. Ascertainment of the past, incident and persistent HPV infection of cervix uteri - detection of HPV DNA in cervical smear and type-specific antibodies against vaccinal HPV typesin blood. Monitoring of the vaccine efficacy for the protection of a consequent infection with vaccinal or closely related types and of possible occurrence of atypical findings or lesions on cervix uteri in women infected immediately before they received the first dose of the vaccine.

Sledování prevalence HPV typů ve vakcinované populaci žen ČR. Detekce předchozí, současné a persistující HPV infekce sliznice děložního hrdla ? přítomnost HPV DNA ve stěru z děložního hrdla a typově specifických protilátek proti vakcinačním typům HPV. Sledování vlivu vakcinace na následnou infekci vakcinačními a příbuznými typy HPV a případný vznik atypií/lézí na děložním hrdle u žen, které byly infikovány vakcinačními typy HPV před aplikací vakcíny.

• MeSH
• infekce papilomavirem epidemiologie   MeSH
• longitudinální studie MeSH
• nádory děložního čípku etiologie   MeSH
• prevalence MeSH
• vakcíny proti papilomavirům MeSH
• věkové faktory MeSH
• Geografické názvy
• Česká republika MeSH

• Konspekt
• Gynekologie. Porodnictví
• NLK Obory
• gynekologie a porodnictví
• epidemiologie
• infekční lékařství
• NLK Publikační typ
• závěrečné zprávy o řešení grantu IGA MZ ČR

• Publikační typ
• abstrakt z konference MeSH